SCHEMBL5077868

SCHEMBL5077868

O=C(O)C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)CO

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.64
LMNA P02545 2/20 0.59
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.50
USP2 O75604 1/20 0.48
SLCO1B1 Q9Y6L6 1/20 0.48
KDM4E B2RXH2 2/20 0.37
OR51E2 Q9H255 1/20 0.33
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10338405 1.00 PDE4A (0.64) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL16280148 1.00 PDE4A (0.64) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL20591201 1.00 PDE4A (0.64) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL13518379 1.00 PDE4A (0.64) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL15121487 1.00 PDE4A (0.64) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL15121486 1.00 PDE4A (0.64) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL725570 1.00 PDE4A (0.64) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL28350552 0.98 PDE4A (0.67) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL8343201 0.98 PDE4A (0.67) PDE4ALMNATDP1L3MBTL1USP2
SCHEMBL29356160 0.98 PDE4A (0.67) PDE4ALMNATDP1L3MBTL1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10717718-B2 5-azido-5-deoxy-2 :3-isopropylidene-D-arabinose compounds; their method of manufacture and their use for the synthesis of ARA-N3, KDO-N3 and 4EKDO-N3 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2020-07-21 US claimed
US-20200209238-A1 OPTIMIZING DIAGNOSTICS FOR GALACTOFURANOSE CONTAINING ANTIGENS THE JOHNS HOPKINS UNIVERSITY 2020-07-02 US claimed
US-20180370942-A1 NEW 5-AZIDO-5-DEOXY-2 :3-ISOPROPYLIDENE-D-ARABINOSE COMPOUNDS; THEIR METHOD OF MANUFACTURE AND THEIR USE FOR THE SYNTHESIS OF ARA-N3, KDO-N3 AND 4EKDO-N3 CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (CNRS) (FR) 2018-12-27 US claimed
US-20230173064-A1 DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF HEPHAISTOS-PHARMA (FR) 2023-06-08 US disclosed
EP-4103726-A1 KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS Inbiose N.V. (BE) 2022-12-21 EP disclosed
US-20220062849-A1 METHOD AND DEVICE FOR PRODUCING SACCHARIDES AND SACCHARIDE ARRAYS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-03-03 US disclosed
WO-2021160828-A1 KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS INBIOSE N.V. (BE) 2021-08-19 WO disclosed
US-10717718-B2 5-azido-5-deoxy-2 :3-isopropylidene-D-arabinose compounds; their method of manufacture and their use for the synthesis of ARA-N3, KDO-N3 and 4EKDO-N3 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2020-07-21 US disclosed
US-20200209238-A1 OPTIMIZING DIAGNOSTICS FOR GALACTOFURANOSE CONTAINING ANTIGENS THE JOHNS HOPKINS UNIVERSITY 2020-07-02 US disclosed
US-10624984-B2 Aptamer-modified polymeric materials for the binding of factors in a wound environment KCI LICENSING, INC. (US) 2020-04-21 US disclosed
US-10359398-B2 Method for determining carbohydrates structure MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2019-07-23 US disclosed
US-20170246341-A1 AMINE-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2017-08-31 US disclosed
US-20170190828-A1 SULFHYDRYL-FUNCTIONALIZED POLYMERIC COMPOSITIONS FOR MEDICAL DEVICES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2017-07-06 US disclosed
US-20160346421-A1 APTAMER-MODIFIED POLYMERIC MATERIALS FOR THE BINDING OF FACTORS IN A WOUND ENVIRONMENT SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2016-12-01 US disclosed
US-20160131649-A1 MICROBIAL GLYCANS AS A TARGET OF HUMAN INTELECTIN NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-05-12 US disclosed
US-20140179624-A1 CYTOPROTECTIVE DERIVATIVES OF AVICIN D AND METHODS OF MAKING AND USING THEREOF RESEARCH DEVELOPMENT FOUNDATION (US) 2014-06-26 US disclosed
US-20080075742-A1 Compositions Comprising Fetal Hemoglobin and Bacterial Endotoxin and Optionally Additional Fetal Liver Components Clinique La Prairie S.A. (CH) 2008-03-27 US disclosed
US-6833451-B2 Phenol, water solvent extraction using a protease PHARMA-ZENTRALE GMBH (DE) 2004-12-21 US disclosed
EP-0829104-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1998-03-18 EP disclosed
WO-1996035239-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179624-A1 CYTOPROTECTIVE DERIVATIVES OF AVICIN D AND METHODS OF MAKING AND USING THEREOF FANCD2, NQO1, BAX PDE4A 3208/4885LMNA 863/4885TDP1 3545/4885
US-20180370942-A1 NEW 5-AZIDO-5-DEOXY-2 :3-ISOPROPYLIDENE-D-ARABINOSE COMPOUNDS; THEIR METHOD OF MANUFACTURE AND THEIR USE FOR THE SYNTHESIS OF ARA-N3, KDO-N3 AND 4EKDO-N3 GALE, ALDOA, DERA PDE4A 1614/4885LMNA 2200/4885TDP1 4634/4885
US-20230173064-A1 DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF LRBA, LITAF, CD14 PDE4A 2080/4885LMNA 336/4885TDP1 4723/4885
US-10624984-B2 Aptamer-modified polymeric materials for the binding of factors in a wound environment SDF4, PCLAF, CCL2 PDE4A 695/4885LMNA 3007/4885TDP1 759/4885
US-20220062849-A1 METHOD AND DEVICE FOR PRODUCING SACCHARIDES AND SACCHARIDE ARRAYS MGAM, SORD, FUT5 PDE4A 2311/4885LMNA 4832/4885TDP1 2731/4885
US-10717718-B2 5-azido-5-deoxy-2 :3-isopropylidene-D-arabinose compounds; their method of manufacture and their use for the synthesis of ARA-N3, KDO-N3 and 4EKDO-N3 GALE, ALDOA, DERA PDE4A 1898/4885LMNA 1793/4885TDP1 4609/4885
US-20160131649-A1 MICROBIAL GLYCANS AS A TARGET OF HUMAN INTELECTIN HINT1, DERL1, ENGASE PDE4A 4264/4885LMNA 2955/4885TDP1 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.